S. Korea unlikely to buy problematic H1N1 vaccine from GSK
GSK | Quote | Chart | News | PowerRating -- South Korea will likely not order a vaccine against the Influenza A (H1N1) virus made by GlaxoSmithKline Plc. (GSK) after the product seemed to have caused a series of severe allergic reactions in Canada, health authorities said Wednesday.
Distribution of the "Aprepanrix" vaccine made by the Britain-based pharmaceutical company has been halted in Canada after it was linked to six cases of anaphylactic shock, which leads to breathing problems and a sudden drop in blood pressure.
The South Korean government earlier made a purchase agreement with GSK to secure 3 million doses of the vaccine within the year, but the deal fell through due to disagreements over its terms, health authorities said.
"The government is currently using only local vaccines," a health official said on condition of anonymity. "We have no plans to bring in foreign vaccines as we are able to produce enough domestically."
A GSK official also said the company does not plan to independently supply the vaccine in South Korea, even if no contract is signed with the government.
For full details on GlaxoSmithKline (GSK) GSK. GlaxoSmithKline (GSK) has Short Term PowerRatings at TradingMarkets. Details on GlaxoSmithKline (GSK) Short Term PowerRatings is available at This Link.
- Zacks Sell List Highlights: BancorpSouth, Inc., Aetna Inc., GlaxoSmithKline plc and Airgas, Inc. - 02/09/10
- Ligand Announces Fourth Quarter and Full Year 2009 Consolidated Financial Results - 02/09/10
- GlaxoSmithKline not to acquire 5% stake in Dr. Reddy's Laboratories - 02/08/10
- Nabi Biopharmaceuticals Completes Another PentaStaph(TM) Milestone - 02/08/10
- Transparency Could Hamper Thought Leader Relationships, Says Cutting Edge Information - 02/08/10
- More News >>
